Ozempic and Wegovy both contain semaglutide, and both are FDA-approved brand-name drugs, but each is approved for different uses. Compounded semaglutide is a different kind of product: the FDA says compounded drugs are not FDA approved, and HealFastRx offers compounded semaglutide through an online visit that it says connects you with a licensed provider.
Also searched as heal fast rx. It is the same HealFastRx service.
Affiliate disclosure: Plainly, some links on this page are affiliate links. Buying through them may earn us a commission. You pay no more either way.
Is semaglutide the same as compounded semaglutide?
Semaglutide is the active ingredient in both Ozempic and Wegovy. Compounded semaglutide is a separate product. The seller's refund policy says compounded medications “are prepared pursuant to an individual patient's prescription and cannot be returned or restocked.” The FDA's FDA's page on unapproved GLP-1 drugs states plainly: “compounded drugs are not FDA approved.”
A 2026 study in The Annals of Pharmacotherapy looked at compounded products found on compounding sites. Its authors searched between February 3 and March 20, 2025, and identified 33 unique semaglutide or tirzepatide products that differed from FDA-approved products. The authors said the popularity of these products as an alternative to FDA-approved medicines is concerning, because their safety and efficacy are largely unknown. The study covered products found across many sites, not one seller. You can read the full abstract in the 2026 Annals of Pharmacotherapy study.
Is Ozempic and Wegovy the same medication?
They share an ingredient but are approved for different things. A 2025 American Journal of Managed Care review says semaglutide is FDA approved under the brand name Ozempic for treatment of type 2 diabetes, and under the brand name Wegovy for the treatment of overweight or obesity.
The Wegovy label on DailyMed lists three approved uses: to reduce major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight; long-term weight reduction; and noncirrhotic MASH with moderate to advanced liver fibrosis (accelerated approval).
How do Ozempic, Wegovy and compounded semaglutide compare?
The table sets the brand-name drugs against compounded semaglutide. Brand facts come from the Wegovy label and the 2025 review, compounded facts come from the FDA, and the last column is HealFastRx's own pages.
| Question | Brand-name drug (per its label) | Compounded drug (per FDA) | What the seller says |
|---|---|---|---|
| What is the active ingredient? | Semaglutide, approved under the Ozempic and Wegovy brand names | FDA's page covers compounded versions of semaglutide and tirzepatide | The homepage lists Compounded Semaglutide as a weekly injection |
| Is it FDA approved? | Yes, under the Ozempic and Wegovy brand names | No: “compounded drugs are not FDA approved” | The FDA has not evaluated the medications for safety, quality, or efficacy |
| What is it approved for? | Wegovy: long-term weight reduction, plus two other uses on its label. Ozempic: type 2 diabetes | No approved use, because it is not FDA approved | Clinician-guided weight management. Prescription treatment requires medical evaluation and is not guaranteed |
| Who makes or dispenses it? | Wegovy's labeler is Novo Nordisk Pharmaceutical Industries, LP | FDA says patients should fill the prescription at a state-licensed pharmacy | Compounded GLP-1s come exclusively from licensed U.S. 503A pharmacies |
| What are the main risks? | A boxed warning for thyroid C-cell tumors. Most common adverse reactions: nausea, diarrhea, vomiting, constipation and abdominal pain | FDA has received 990 adverse event reports for compounded semaglutide as of May 31, 2026, and reports of dosing errors | GLP-1 medications carry serious risks, including thyroid C-cell tumors and medullary thyroid carcinoma |
What are the side effects and safety warnings?
The Wegovy label carries a boxed warning titled “WARNING: RISK OF THYROID C-CELL TUMORS.” It says that in rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors, and that it is unknown whether Wegovy causes these tumors in humans. The label lists nausea, diarrhea, vomiting, constipation and abdominal pain as its most common adverse reactions, at an incidence of 5% or more. It lists a personal or family history of MTC or MEN 2, and a prior serious hypersensitivity reaction to semaglutide or any of its excipients, as contraindications.
For compounded versions, the FDA says it “has received reports of adverse events related to compounded versions of semaglutide and tirzepatide.” Some of those reports required hospitalization and may be related to dosing errors. The FDA says these “resulted from patients measuring and self-administering incorrect doses of the drug.” It also says it “is aware of fraudulent compounded semaglutide and tirzepatide marketed in the U.S.,” and that counterfeit drugs “claim to be authentic, but could contain the wrong ingredients.”
A 2026 FAERS safety study of compounded GLP-1s used the FDA's adverse event reporting system from 2018 to 2024. It covered 81,078 GLP-1 receptor agonist reports, 707 of which involved compounded products. Compared with non-compounded products, compounded ones had higher reporting odds for abdominal pain, diarrhea, nausea, suicidality and cholecystitis, and higher odds of hospitalization. The study was not designed to show a cause-and-effect relationship.
The 2025 American Journal of Managed Care review says compounded semaglutide products “may lack the quality controls historically seen with compounded formulations, resulting in risks for dosing errors and adverse health outcomes.” A 2023 case series in the Journal of the American Pharmacists Association reported three cases. Two patients self-administered 10-fold dosing errors, and the authors noted that compounded semaglutide vials do not use the safety features of prefilled manufactured pens.
What do studies say about compounded semaglutide results?
A 2025 retrospective study in Diabetes, Obesity and Metabolism followed 94 people in a commercial wellness studio setting who received once-weekly compounded semaglutide/cyanocobalamin injections from June 2023 to January 2024. After 3 months, average weight loss was 4.11 kg, or 4.57% of body weight. The study also measured losses of lean and skeletal muscle mass alongside fat loss.
For the brand-name trial results and how they compare, see semaglutide and tirzepatide clinical trials.
What does HealFastRx say about its own product?
HealFastRx's sales image labels the product “Semaglutide, COMPOUNDED INJECTION, RX ONLY.” Its pages say the following.
| Item | What the seller's pages say |
|---|---|
| Product | Compounded Semaglutide, weekly injection (homepage) |
| Pharmacy | Licensed U.S. 503A pharmacies (homepage) |
| Medical decision | A licensed provider decides whether a prescription is medically appropriate (terms and conditions) |
| Age | You must be at least 18, or the age of majority in your state if higher (terms and conditions) |
| Product Page | Product Page |
The seller's pages also differ in a few places. Read them side by side before you order:
- Availability: the homepage and contact page say “Licensed Providers in All 50 States.” The shipping policy says HealFastRx “currently provides prescription fulfillment only within eligible jurisdictions in the United States,” and the footer says availability “may vary by state.”
- Delivery: the homepage says treatment “arrives at your door in 2 days.” The shipping policy says medications “typically ship within 2 to 3 business days after provider approval and pharmacy processing,” and that delivery estimates “are not guaranteed.”
- Ownership: the homepage says “Physician-Founded & Led.” The About page shows a placeholder reading “[VERIFY WITH HEALFAST] Company history, founding physicians and any credential statements to be supplied and confirmed before launch.”
- Emergencies: the terms say the service “is not appropriate for emergency care or urgent care,” and tell you to call 911 for a medical emergency.
What does it cost, and can you get a refund?
Prices as of November 5, 2026: the homepage lists Semaglutide at $99 for the first month, then $199 a month. It says you can “Save with 3, 6 & 12-month plans,” and that “Medication, Supplies, Provider Care, 24/7 Support, Coaching Materials + Shipping Included” come with the offer.
The refund policy, effective August 7, 2026, is the trade-off to plan around. Compounded medications cannot be returned or restocked. Refunds are generally not available just because you are dissatisfied with a prescription medication. To avoid a recurring charge, cancellation requests must be submitted before the applicable renewal begins processing.
How do I check an online pharmacy before I order?
The FDA's FDA's guide to considering an online pharmacy says a safe online pharmacy “is licensed with a state board of pharmacy.” It lists as a warning sign one that “is not licensed in the United States and by your state board of pharmacy.” The FDA also says patients should “obtain a prescription from their doctor and fill the prescription at a state-licensed pharmacy.”
What are the other options to compare?
For a side-by-side look at the brand-name choices, read wegovy vs ozempic. If you want non-prescription options to think about, wegovy alternatives for healthy weight loss covers what research says about them.
Before you order
- Ask which state-licensed pharmacy would fill your prescription, and for its license details.
- Ask which states the service covers, since the seller's pages differ on this.
- Ask for the exact formulation of your compounded product and its beyond-use date.
- Ask your clinician whether a brand-name drug or a compounded product fits your health history.
By SterlingMedicalCenter.org Editorial Team
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.
The source facts for this page were checked by a person on our team on November 9, 2026.
Read next